Headquartered in Halle (Saale), Germany, Probiodrug AG is a publicly traded (Euronext Amsterdam: PBD) clinical stage biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease (AD).
Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. It is addressing a key neuro-/synaptotoxic component of the AD-pathology, pyroglutamate-Abeta (pGlu-Abeta), using a double pronged strategy: inhibition of its production by the enzyme Glutaminylcyclase (QC) and increasing clearance by a pGlu-Abeta specific antibody. Its lead product, the small molecule PQ912, has successfully completed a Phase 2a (SAPHIR) study; the company has initiated the preparation of a Phase 2b core program. Probiodrug´s pipeline also includes PBD-C06, an anti-pGlu-Abeta-specific monoclonal antibody, which is in preclinical development.
Founded in 1997 by Hans-Ulrich Demuth and Konrad Glund, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Today, Probiodrug aims to become a leading company in the development of AD treatments and to thereby provide a better life for Alzheimer’s disease patients.